Erudio Healtherudio.com
Drug
Turmetabart adizutecan trials: what clinicians said in public
An HCP commentary report on 1 clinical trial studying turmetabart adizutecan: M23-385. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 2 more trials with public commentary and no report yet.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| M23-385 NCT05599984 · AbbVie | advanced solid tumors | Phase 1 | 69 | 18 | Focused | Nov 21, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| SEZanne NCT07155174 · AbbVie FocusedView → | previously untreated extensive-stage small cell lung cancer | Phase 2 | Focused | View | |||
| NCT07365241 NCT07365241 · AbbVie FocusedView → | relapsed/refractory small cell lung cancer | Phase 3 | Focused | View | |||